Association between NSAID use and mortality risk in patients with end-stage renal disease: a population-based cohort study

References

• Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–1982. doi:10.1016/S0140-6736(14)61601-925777665
   PubMed Web of Science ®Google Scholar
• Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14:82–99. doi:10.1053/j.ackd.2006.10.00117200048
   PubMed Web of Science ®Google Scholar
• Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42:1239–1247. doi:10.1053/j.ajkd.2003.08.02514655196
   PubMed Web of Science ®Google Scholar
• Brkovic T, Burilovic E, Puljak L. Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review. Patient Prefer Adherence. 2016;10:1131–1150.27382261
   PubMed Web of Science ®Google Scholar
• Santoro D, Satta E, Messina S, Costantino G, Savica V, Bellinghieri G. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin Nephrol. 2013;79(Suppl 1):S2–S11.23249527
   PubMedGoogle Scholar
• Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42:217–228. doi:10.1016/S0272-6386(03)00645-012900801
   PubMed Web of Science ®Google Scholar
• Pai AB, Cardone KE, Manley HJ, et al. Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach. Clin J Am Soc Nephrol. 2013;8:1988–1999. doi:10.2215/CJN.0142021323990162
   PubMed Web of Science ®Google Scholar
• Mathew RO, Bettinger JJ, Wegrzyn EL, Fudin J. Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease. J Pain Res. 2016;9:1191–1195. doi:10.2147/JPR.S12527027994481
   PubMed Web of Science ®Google Scholar
• Barakzoy AS, Moss AH. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol. 2006;17:3198–3203. doi:10.1681/ASN.200605047716988057
   PubMed Web of Science ®Google Scholar
• Williams AW, Dwyer AC, Eddy AA, et al. Critical and honest conversations: the evidence behind the “Choosing Wisely” campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol. 2012;7:1664–1672. doi:10.2215/CJN.1025101122977214
   PubMed Web of Science ®Google Scholar
• Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014;27:188–204. doi:10.1111/sdi.2014.27.issue-224517512
   PubMed Web of Science ®Google Scholar
• Wu J, Ginsberg JS, Zhan M, et al. Chronic pain and analgesic use in CKD: implications for patient safety. Clin J Am Soc Nephrol. 2015;10:435–442. doi:10.2215/CJN.0652071425710806
   PubMed Web of Science ®Google Scholar
• Heleniak Z, Cieplińska M, Szychliński T, et al. Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. J Nephrol. 2017;30:781–786. doi:10.1007/s40620-016-0352-z27679400
   PubMed Web of Science ®Google Scholar
• Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med. 2011;9:423–430. doi:10.1370/afm.130221911761
   PubMed Web of Science ®Google Scholar
• Davison SN. Pain, analgesics, and safety in patients with CKD. Clin J Am Soc Nephrol. 2015;10:350–352. doi:10.2215/CJN.0060011525710800
   PubMed Web of Science ®Google Scholar
• National Health Insurance Administration, Ministry of Health and Welfare. Universal Health Coverage in Taiwan. 2018 Available from: https://www.nhi.gov.tw/English/Content_List.aspx?n=8FC0974BBFEFA56D&topn=ED4A30E51A609E49. Accessed 17, 2019.
   Google Scholar
• Lee YW, Chen TL, Shih YR, et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer. 2014;120:1338–1344. doi:10.1002/cncr.2857924496917
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.1607900
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Guthrie B, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88:859–866. doi:10.1038/ki.2015.2926221754
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2019. Oslo, Norway: WHO Collaborating Centre; 2018 Available from: https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf. Accessed January 7, 2019.
   Google Scholar
• Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087. doi:10.1136/bmj.c29320228141
   PubMed Web of Science ®Google Scholar
• Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies. Kidney Int. 2012;81:341–350.22089946
   PubMed Web of Science ®Google Scholar
• Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int. 2014;85:158–165. doi:10.1038/ki.2013.25223802192
   PubMed Web of Science ®Google Scholar
• Tong J, Liu M, Li H, et al. Mortality and associated risk factors in dialysis patients with cardiovascular disease. Kidney Blood Press Res. 2016;41:479–487. doi:10.1159/00044344927434642
   PubMed Web of Science ®Google Scholar
• McQuillan R, Trpeski L, Fenton S, Lok CE. Modifiable risk factors for early mortality on hemodialysis. Int J Nephrol. 2012;2012:435736. doi:10.1155/2012/43573622888426
   PubMedGoogle Scholar
• Kimmel PL, Fwu CW, Abbott KC, Eggers AW, Kline PP, Eggers PW. Opioid prescription, morbidity, and mortality in United States dialysis patients. J Am Soc Nephrol. 2017;28:3658–3670. doi:10.1681/ASN.201608088628935654
   PubMed Web of Science ®Google Scholar
• Hsu HJ, Wu IW, Hsu KH, et al. The association between chronic musculoskeletal pain and clinical outcome in chronic kidney disease patients: a prospective cohort study. Ren Fail. 2019;41:257–266. doi:10.1080/0886022X.2019.159681731014149
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169:141–149. doi:10.1001/archinternmed.2008.52519171810
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–2235. doi:10.1161/CIRCULATIONAHA.110.00467121555710
   PubMed Web of Science ®Google Scholar
• Taiwan Society of Nephrology. Taiwan chronic kidney disease clinical guidelines. 2015 Available from: https://www.tsn.org.tw/. Accessed 426, 2019.
   Google Scholar
• Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 382;2013:769–779. doi:10.1016/S0140-6736(13)60900-923726390
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammaroty drugs: network meta-analysis. BMJ. 2011;342:c7086. doi:10.1136/bmj.c708621224324
   PubMed Web of Science ®Google Scholar
• Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37:1015–1023. doi:10.1093/eurheartj/ehv50526984863
   PubMed Web of Science ®Google Scholar
• Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195. doi:10.1136/bmj.f116423757736
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15. doi:10.1172/JCI2729116395396
   PubMed Web of Science ®Google Scholar
• Jankovic SM, Aleksic J, Rakovic S, et al. Nonsteroidal anti-inflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. J Nephrol. 2009;22:502–507.19662606
   PubMed Web of Science ®Google Scholar
• Hsu CC, Chang YK, Hsu YH, et al. Association of nonsteroidal anti-inflammatory drug use with stroke among dialysis patients. Kidney Int Rep. 2017;2:400–409. doi:10.1016/j.ekir.2017.06.00729142967
   PubMed Web of Science ®Google Scholar
• Prichard SS. Comorbidities and their impact on outcome in patients with end-stage renal disease. Kidney Int. 2000;57(suppl 74):S100–S104. doi:10.1046/j.1523-1755.2000.07417.x
   Web of Science ®Google Scholar
• Storey BC, Staplin N, Harper CH, et al. Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. Kidney Int. 2018;93:1165–1174. doi:10.1016/j.kint.2017.11.02029395337
   PubMed Web of Science ®Google Scholar
• Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114:254–259. doi:10.1016/j.jfma.2013.09.00924140108
   PubMed Web of Science ®Google Scholar